IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

Group 1 - IMUNON, Inc. has entered into a securities purchase agreement for the sale of 1,939,114 shares of common stock and warrants to purchase an equal number of shares, priced at $3.61 each [1][2] - The gross proceeds from the offering are expected to be approximately $7.0 million before deducting fees and expenses [2] - The offering is expected to close on or about December 31, 2025, subject to customary closing conditions [2] Group 2 - Maxim Group LLC is the lead placement agent, with Brookline Capital Markets acting as co-placement agent for the offering [2] - The securities are being offered under a "shelf" registration statement on Form S-3, which was declared effective by the SEC on May 22, 2024 [3] - A prospectus supplement and accompanying prospectus will be filed with the SEC regarding the registered direct offering [3] Group 3 - IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments that utilize the body's natural mechanisms for effective responses to various diseases [5]